Evaluation of purine and pyrimidine analogues in human tumor cells from patients with low-grade lymphoproliferative disorders using the FMCA

European Journal of Haematology

Volumn 62, Issue 5, 1999, Pages 293-299

  Åleskog, Anna ^a   Larsson, R ^a   Hoglund M ^a   Sundstrom C ^a   Kristensen, J ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

FMCA; Low grade lymphoproliferative disorders; Purine analogues; Pyrimidine analogues

Indexed keywords

CLADRIBINE; CYTARABINE; FLUDARABINE; GEMCITABINE; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CYTOTOXICITY TEST; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SENSITIVITY; DRUG STRUCTURE; FEMALE; FLUORESCENCE ANALYSIS; FLUOROMETRY; HUMAN; HUMAN CELL; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 0032923697     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1999.tb01905.x     Document Type: Article

References (31)

1. Pott-Hoeck C, Hiddemann W. Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias. Ann Oncol 1995;6:421-433.
2. Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet 1992;340:952-956.
3. Hochster HS, Kim K, Green MD, et al. Activity of fludarabine in previously-treated non-Hodgkin's low-grade lymphoma. Results of an Eastern Cooperative Oncology Group Study. J Clin Oncol 1992;10: 28-32.
4. Marlton P, McCarthy C, Taylor K. Fludarabine-induced cytogenic remission in prolymphocytic leukemia. Am J Hematol 1992;40:71-72.
5. Tallman MS, Hakimian D. Purine nucleoside analogs: Emerging roles in indolent lymphoproliferative disorders. Blood 1995;86:2463-2474.
6. Robertsson LE, Clubb C, Meyn R, et al. Induction of apoptotic cell death in CLL by 2-chlorodeoxyadenosine and 9-ß-D-arabinosyl-2-fluoroadenine. Blood 1993; 81:143-150.
7. Bishop J, Matthews J, Young G, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996;87:1710-1717.
8. Cormier Y, Eisenhauer E, Muldal A, et al. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer. Ann Oncol 1994;5:283-285.
9. Pollera CF, Ceribelli A, Crecco M, et al. Weekly gemcitabine in advanced bladder cancer: A preliminary report from phase I study. Ann Oncol 1994;5:182-184.
10. Lund B, Hansen O, Theiladf K, et al. Phase II study of gemcitabine (2,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994; 86:1530-1533.
11. Csoka K, Liljemark J, Larsson R, et al. Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors. Seminars in Oncology 1995;22:47-53.
12. Bouffard DY, Momparler LF, Momparler RL. Comparision of antineoplastic activity of 2′,2′-difluorodeoxycytidine and cytosine arabinoside against human myloid and lymphoid leukemic cells. Anticancer Drugs 1991;2:49-55.
13. Larsson R, Kristensen J, Sandberg C, et al. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia using a flourometric microculture cytotoxicity assay (FMCA). Int J Cancer 1992;50:177-185.
14. Nygren P, Kristensen J, Jonsson B, et al. Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia. Leukemia 1992;6:1121-1128.
15. Nygren P, Hagberg H, Glimelius B, et al. In vitro drug sensitivity testing of tumor cells from patients with non-Hodgkin's lymphoma using the fluorometric cytotoxicity assay. Ann Oncol 1994;5:127-131.
16. Harris NL, Jaffe ES, Stein H, et al. A revised European American classification of lymphoid neoplasms: A proposal from the international lymphoma study group. Blood 1994;84:1361-1392.
17. Csoka K, Larsson R, Tholande B, et al. Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the flourometric cytotoxicity assay (FMCA). Gynecol Oncol 1994;54:163-170.
18. Larsson R, Nygren P, Ekberg M, et al. Chemotherapeutic drug sensitivity testing of human leukemia cells in vitro using a semiautomated flourometric assay. Leukemia 1990;4:567-571.
19. Santana VM, Hurwitz CA, Blakley RL. Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia. Blood 1994;84:1237-1242.
20. Gandhi V, Estey E, Keating MJ, et al. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogeneous leukemia during therapy. J Clin Oncol 1993;11:116-124.
21. Juliusson G, Liljemark J. 2-Chlorodeoxyadenosine with and without cytosin arabinoside and idarubicin for acute myeloid and lymphoid leukemia clinical and pharmacokinetic studies. Br J Haematol 1994;87 (suppl 1) 12 (abstract #48).
22. Larsson R, Fridborg H, Liljemark J, et al. In vitro activity of 2-chlorodeoxyadenosine (CdA) in primary cultures of hematological and solid tumors. Eur J Cancer 1994;30A:1022-1026.
23. Nygren P, Fridborg H, Csoka K, et al. Detection of tumor-specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. Int J Cancer 1994;56:715-720.
24. Robertsson LE, Hall R, Keating MJ, et al. High-dose cytosine arabinoside in chronic lymphocytic leukemia: A clinical and pharmacologic analysis. Leukemia and Lymphoma. 1993;10:43-48.
25. Caballero MD, Gonzalez M, Canizo MC, et al. Concomitant chronic lymphocytic leukemia (CLL) and acute myeloid leukemia. Complete remission of CLL achieved with high-dose cytosin arabinoside. Leukemia 1992;6:856-858.
26. Bernell P, Ohm L. Promising activity of gemcitabine in refractory high-grade non-Hodgkin's lymphoma. Br J Hematol 1998;101:202-204.
27. Juliusson G, Elmhorn-Rosenberg A, et al. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 1992;327:1056-1061.
28. Delannoy A, Hanique G, Ferrant A. 2-chlorodeoxyadenosine for patients with B-cell chronic lumphocytic leukemia resistant to fludarabine. N Engl J Med 1993; 328:812.
29. Saven A, Lemon RH, Piro LD. 2-chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 1993; 328:812-813.
30. O'Brien S, Kantarjian H, Estey E, et al. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med 1994;330:319-322.
31. Bosanquet AG, Bell PB. Novel ex vivo analysis of nonclassical, pleiotropic drug resistance and collateral sensitivity induced by therapy provides a rationale for treatment strategies in chronic lymphocytic leukemia. Blood 1996;87:1962-1971.